Research
Hormonal
Body weight decreased from 123.9 ± 23.5 kg to 118.9 ± 22.9 kg over 6 months (P < 0.001).
Clinicians may observe weight loss in T2DM patients treated with semaglutide.
StrongSupportsmedium confidence
Average A1c and body weight also decreased from baseline to 6 months (123.9 ± 23.5 kg and 118.9 ± 22.9 kg, P < 0.001, respectively).
Why this rating
Based on the retrospective medical record review of 72 patients.
Source
The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes
Jodi Meyer et al. · Annals of Pharmacotherapy · 2022
DOI 10.1177/10600280221107381
other · n=72Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →